Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New spray could quench thirst for ICU patients on ventilators

NCT ID NCT07533552

Symptom relief Sponsor: Yeh,Shiao Feng Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 2 times

Summary

This study tests whether an enzyme-based mouth spray can better relieve intense thirst in ICU patients who have a breathing tube, compared to a distilled water spray. Thirst is very common in these patients and can cause anxiety or complications. The trial involves 76 adults in Taiwan, who will receive either the enzyme spray or water spray after routine mouth care, and their thirst will be measured over four hours.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

76 people

The number who actually took part.

Started

Apr 2026

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients aged ≥18 years admitted to the intensive care unit (ICU) with endotracheal intubation, and an expected duration of intubation \>24 hours. * Thirst intensity score ≥3 on the Numerical Rating Scale for Thirst Intensity (NRS-I). * Conscious and able to communicate subjective sensations verbally (Mandarin or Taiwanese) or in written form. * Richmond Agitation-Sedation Scale (RASS) score between -1 and +1. * Willingness to participate and provision of written informed consent after a full explanation of the study. Exclusion Criteria: * Known allergy to enzyme spray components (e.g., lysozyme, lactoperoxidase, glucanase, xylitol). * Known allergy to milk or eggs. * Pre-existing xerostomia. * Presence of oral mucosal ulcers or active oral bleeding. * History of oral surgery. * Physician-diagnosed abnormal salivary secretion. * Physician-determined increased risk of aspiration or other complications associated with oral spray administration.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THIRST are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THIRST

Contacts and locations

Locations

  • Chi Mei Medical Center

    Tainan, Tainan City, 710, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.